- ICH GCP
- Registre des essais cliniques de l'UE
Derniers essais
EudraCT Number: 2004-005013-11 | Sponsor Protocol Number: D2452L00007 | Start Date: 2005-02-01 | ||||||
Sponsor Name: Umeå University Hospital | ||||||||
Full Title: A 36 wk three-center double-blind randomized three-way cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo. The MEDICA study Mechanisms for the diabetes-p... | ||||||||
Medical condition: The "metabolic syndrome" is a cluster of metabolic and cardiovascular risk factors. Insulin resistance appears to be a central disease mechanism and hypertension is another important component. A t... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: SE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001666-40 | Sponsor Protocol Number: CZOL446H2202E1 | Start Date: 2005-02-01 | ||||||
Sponsor Name: Novartis Pharma AG | ||||||||
Full Title: An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfe... | ||||||||
Medical condition: Osteogenesis Imperfecta | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: HU (Prematurely Ended) GB (Completed) BE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-004516-22 | Sponsor Protocol Number: 04-4025 | Start Date: 2005-02-01 | ||||||
Sponsor Name: Uppsala University | ||||||||
Full Title: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder. | ||||||||
Medical condition: Premenstrual Dysphoric Disorder | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: SE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003657-99 | Sponsor Protocol Number: CP 204 | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: Arrow Therapeutics Ltd | |||||||||||||
Full Title: A double-blind, randomised, placebo controlled study to evaluate the safety and efficacy of A-60444 in adults with RSV infection following stem cell transplantation | |||||||||||||
Medical condition: Upper respiratory tract infection (as identified by regular surveillance of stem cell transplant patients) or stem cell transplant patients diagnosed as positive for respiratory syncytial virus (RSV). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005106-79 | Sponsor Protocol Number: ST1481-DM02-008 | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: Sigma Tau industrie Farmaceutiche Riunite Spa | |||||||||||||
Full Title: Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimen | |||||||||||||
Medical condition: advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003996-35 | Sponsor Protocol Number: IPERBRO | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: UNIVERSITA DEGLI STUDI DI UDINE | |||||||||||||
Full Title: randomized,double blind, placebo-controlled trial of the effect of treatment with 3 hypertonic salin solution on bronchiolitis | |||||||||||||
Medical condition: Nebulized 3 hypertonic saline solution to improve clinical outcomes in children with bronchiolitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003752-19 | Sponsor Protocol Number: OXN3401 | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: Mundipharma Research GmbH & Co.KG | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged-release Tablets in Subjects with ... | |||||||||||||
Medical condition: Moderate to severe chronic pain of low back that requires around-the-clock opioid therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DK (Completed) SK (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002629-36 | Sponsor Protocol Number: 0881A6-101764 | Start Date: 2005-02-01 | ||||||
Sponsor Name: Wyeth Pharmaceuticals, Global Medical Affairs Department | ||||||||
Full Title: A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis | ||||||||
Medical condition: psoriasis | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: HU (Completed) AT (Completed) SE (Completed) IE (Completed) DK (Completed) FI (Completed) CZ (Completed) DE (Completed) GB (Completed) IT (Completed) BE (Completed) ES (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-001177-25 | Sponsor Protocol Number: P04057 | Start Date: 2005-02-01 | ||||||
Sponsor Name: Schering-Plough CE AG Hungarian Commercial Representative Office | ||||||||
Full Title: Cardiac safety profile of Caelyx therapy in anthracyclin pretreated metastatic breast cancer patients. | ||||||||
Medical condition: Women with histologically or cytologically confirmed metastatic breast cancer (no prior chemotherapy for metastatic disease). | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: HU (Prematurely Ended) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000876-14 | Sponsor Protocol Number: P030089-01 | Start Date: 2005-01-31 | |||||||||||
Sponsor Name: FERRER INTERNACIONAL, S.A. | |||||||||||||
Full Title: A multicentre, multinational, parallel, randomised, double blind clinical trial, to evaluate the non-inferiority of Prolonged Release Torasemide (PR) versus Immediate Release Torasemide (IR) in pat... | |||||||||||||
Medical condition: MILD TO MODERATE ARTERIAL HYPERTENSION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |